Psychological distress related to BRCA testing in ovarian cancer patients

被引:24
|
作者
Bjornslett, Merete [1 ,2 ]
Dahl, Alv A. [2 ,3 ]
Sorebo, Oystein [4 ]
Dorum, Anne [5 ]
机构
[1] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Mol Oncol, N-0424 Oslo, Norway
[2] Univ Oslo, Fac Med, Oslo, Norway
[3] Oslo Univ Hosp, Norwegian Radium Hosp, Natl Advisory Ctr Late Effects Canc Treatment, Dept Oncol, Oslo, Norway
[4] Buskerud & Vestfold Univ Coll, Sch Business & Social Sci, Honefoss, Norway
[5] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Gynecol Oncol, Oslo, Norway
关键词
Ovarian cancer; Oncology; BRCA; MICRA; Anxiety; HEREDITARY BREAST; DEPRESSION SCALE; HOSPITAL ANXIETY; RISK; QUESTIONNAIRE; MUTATIONS; DESIGN; IMPACT; WOMEN;
D O I
10.1007/s10689-015-9811-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An increasing demand for genetic testing has moved the procedure from highly selected at-risk individuals, now also including cancer patients for treatment associated testing. The heritable fraction of ovarian cancer is more than 10 %, and our department has offered BRCA testing to such patients irrespective of family history since 2002. This study examined potential psychosocial distress associated with this procedure using The Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire and other patient-rated generic distress instruments. Patients were divided into four groups according to cancer risk: mutation carriers, own history of breast cancer and ovarian cancer, family history of breast cancer and/or ovarian cancer, and patients without family history. In a postal survey, 354 patients responded. Good acceptance of the MICRA was observed, and previously described good psychometric properties were confirmed. A significant association between MICRA total score and receiving a positive BRCA test result was found. No significant between-group differences were observed with generic distress instruments. Time since cancer diagnosis, test result, and survey showed no significant associations with MICRA scores. Internal consistencies of instruments were adequate. Exploratory and confirmatory factor analyses showed adequate fit indices for a three factor solution of the MICRA, but further refinement of the items should be considered. In conclusion, the specific types of worry and distress most relevant to receiving genetic testing irrespective of family history were not captured by the generic distress instruments. The MICRA was supported as a useful tool for detection of mental distress related to genetic testing and risk evaluation.
引用
收藏
页码:495 / 504
页数:10
相关论文
共 50 条
  • [1] Psychological distress related to BRCA testing in ovarian cancer patients
    Merete Bjørnslett
    Alv A. Dahl
    Øystein Sørebø
    Anne Dørum
    Familial Cancer, 2015, 14 : 495 - 504
  • [2] Underuse of BRCA testing in patients with breast and ovarian cancer
    Wright, Jason D.
    Chen, Ling
    Tergas, Ana I.
    Accordino, Melissa
    Ananth, Cande V.
    Neugut, Alfred I.
    Hershman, Dawn L.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (06) : 761 - 763
  • [3] UK BRCA mutation testing in patients with ovarian cancer
    George, Angela
    BRITISH JOURNAL OF CANCER, 2015, 113 : S17 - S21
  • [4] UK BRCA mutation testing in patients with ovarian cancer
    Angela George
    British Journal of Cancer, 2015, 113 : S17 - S21
  • [5] Profile of BRCA testing in ovarian cancer patients in the US and EU
    Tyczynski, J. E.
    Moss, S.
    De Richter, P.
    CLINICAL CANCER RESEARCH, 2015, 21
  • [6] CURRENT GUIDANCE FOR BRCA MUTATION TESTING IN OVARIAN CANCER PATIENTS
    Ehlken, B.
    Driedger, J.
    Hofmann-Xu, L.
    Paulus, G.
    Berger, K.
    de Moor, C.
    Schroeder, C.
    Clune, J.
    Tyczynski, J.
    VALUE IN HEALTH, 2014, 17 (07) : A663 - A663
  • [7] Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives
    Gori, Stefania
    Barberis, Massimo
    Bella, Maria Angela
    Buttitta, Fiamma
    Capoluongo, Ettore
    Carrera, Paola
    Colombo, Nicoletta
    Cortesi, Laura
    Genuardi, Maurizio
    Gion, Massimo
    Guarneri, Valentina
    Incorvaia, Lorena
    La Verde, Nicla
    Lorusso, Domenica
    Marchetti, Antonio
    Marchetti, Paolo
    Norrnanno, Nicola
    Pasini, Barbara
    Pensabene, Matilde
    Pignata, Sandro
    Radice, Paolo
    Ricevuto, Enrico
    Sapino, Anna
    Tagliaferri, Pierosandro
    Tassone, Pierfrancesco
    Trevisiol, Chiara
    Truini, Mauro
    Varesco, Liliana
    Russo, Antonio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 140 : 67 - 72
  • [8] Charity calls for routine BRCA testing of ovarian cancer patients
    Wise, Jacqui
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 347
  • [9] Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance
    Cham, Stephanie
    Landrum, Mary Beth
    Keating, Nancy L.
    Armstrong, Joanne
    Wright, Alexi A.
    JAMA NETWORK OPEN, 2022, 5 (01) : E2142703
  • [10] Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
    Angela George
    Stan Kaye
    Susana Banerjee
    Nature Reviews Clinical Oncology, 2017, 14 : 284 - 296